Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lowman (or anyone), this may be a silly question, however, I don't know the answer so hoping for some help. Where do the financial sites (Yahoo, CNBC, etc.) get their shares counts for Insiders? I can't imagine they go through all of the SEC filings and then have the information input, do they? Does the Transfer Agent have this info? Is it supplied by the company? Or who should I call to get Insider's current holdings?
This is why I'm asking. CNBC listed the COB of a company I follow as holding 303.6M shares as of 12/5. Today it shows the COB holds 307.7M shares.
Per the companies' filings, the outstanding shares were increased from August to December by roughly 4.8M. However, I see no filings during that time frame that says the COB's insider holdings have changed. So I'm confused.
Appreciate any help.
Rambus, what does "H2" mean?
Advanced Cell Technology, Inc. Initiation of Coverage and Informational Review Issued by Scimitar Equity Research of ACTC Proprietary Technology and Development Programs
BOSTON, Jan. 29 /PRNewswire/ -- Scimitar Equity Research, Inc. today
issued a new Informational Review on Advanced Cell Technology, Inc. (OTC
Bulletin Board: ACTC) entitled, "The Road to Commercial Development of New
Therapies from Stem Cells."
Advanced Cell Technology (ACT) is a biotechnology company applying
human embryonic stem (hES) cell technology in the emerging field of
regenerative medicine. ACT is developing novel stem cell-based treatments
and cures to target a variety of serious diseases and injuries. ACTC's lead
therapeutic development programs include stem cell based treatments for
retinal disease such as macular degeneration; diseases of the blood, heart
and circulatory system; and dermatological treatments for repair of skin
damage from surgery, wounds and burns. ACT has entered development
partnerships with leading institutions, and is pursuing additional
partnerships with leading biotechnology companies and organizations
worldwide. ACTC has announced plans to file in 2007 its first
Investigational New Drug Application (IND) with the FDA to treat the eye
condition known as macular degeneration.
The analyst research review of ACTC is available on Scimitar's website:
http://www.scimitarequity.com.
I was just looking at the annual report and it shows that he received 60k in stock compensation (page 15). And then it shows he has approx. 310 million shares which includes 4 million options to buy at a later date. Which leaves roughly 306 million. The CNBC site says 307.7M.
Will have to look through other filings at some point and see if the site was correct when it said 303.6. I don't have time right now - anyone else wants to that would be great.
Yep, looks like that's probably a large portion of it. I was hoping VIP's original statement (12/5) came from Yahoo (not known for accuracy these days) or somewhere other than the same site that Jack got his info from. But just found the post and it's from the same site.
The number of common shares outstanding as of August 1, 2006 was 714,178,528.
http://sec.freeedgar.com/displayText.asp?ID=4586104
On November 30, 2006, the registrant had 718,988,982 shares of common stock issued and outstanding.
http://sec.freeedgar.com/displayHTML.asp?ID=4824817
Anyone know who (or why) these shares were issued?
FWIW, I just called the Transfer Agent and as of record today there are 718,988,982 shares outstanding. She couldn't give me past figures so I have no idea if this has been increased.
I saw at least 3 (who signed up today) since 7pm.
FWIW, I just checked yesterday and there were no new filings on Pacer.
'Tis true!!!! Hooray! And, the icing on the cake...except for airfare - it's a free trip!! My husband won it!!
We're on our way out of town this weekend to celebrate our 15th anniversary (first time alone in 8 years)...then next weekend we're Miami bound! Very exciting couple of weeks ahead.
And, yes, GOOOOOOOOOOOOOOOO BEARRRRRRRRRRRRS!!!!
Woooohooo!! She's beautiful. What did you name her?
Do you mean acronyms? Like "dd", "r/s", etc. If so, here's a board that has quite a few listed.
http://www.investorshub.com/boards/board.asp?board_id=5827
Thanks for the shirt! And, you're right, looks like a high around 78 degrees...just perfect!
Yep, meet me at the Miami Marriott at 2:00 and I'll give you your ticket!
Changing attitudes
Stem cell firm sees hopeful signs in Washington
By Lisa Eckelbecker TELEGRAM & GAZETTE STAFF
leckelbecker@telegram.com
WORCESTER— Advanced Cell Technology Inc. has never been shy about going its own way when it comes to working on embryonic stem cells.
The company, based in California with a laboratory in Worcester, has raised private money and developed its own lines of the controversial cells while also urging politicians to drop government funding restrictions on the work.
But recently Advanced Cell announced that it received a $204,439 grant from the National Institutes of Health to develop molecular tags to track the development of embryonic stem cells. With that grant and a new Congress contemplating looser rules for stem cell funding, Advanced Cell Chairman and Chief Executive William M. Caldwell IV says he senses a political environment that is more supportive of the technology, which could help ease some of the uncertainty about embryonic stem cell businesses.
“It’s not the money that would come out of the federal government” that is most important, Mr. Caldwell said. “It’s the (political) overhang that has been a detriment to the industry seeking corporate partners and more established groups seeking to come in and develop the technologies.”
Stem cells are the body’s master cells, capable of developing into other types of cells. Adult stem cells are found in the body or the umbilical cord blood of newborns. Embryonic stem cells come from the center of embryos that are just a few days old.
Adult stem cells from the blood system have long been used as treatments to rebuild the body’s blood and immune systems. Some scientists think embryonic stem cells could be an even richer source of cellular treatments for ailments such as Parkinson’s disease.
To pluck embryonic stem cells from embryos, however, researchers have followed procedures that destroy the embryos. Opponents of that include the Catholic Church and President Bush, who decided in 2001 that researchers could only get federal funding for embryonic stem cell studies if they used cell batches already in existence.
Federal funding matters in the life sciences because government support often backs early experiments. Pharmaceutical and biotechnology companies typically get involved later by translating basic research into potential human treatments. The earliest embryonic stem cell research may be too risky and too far from commercialization for many corporate investors.
With his decision in 2001, President Bush sought to balance research and ethics, but researchers have complained that the 21 “presidential” cell lines are too few and too compromised by the mouse cells they grew upon to fully support a robust research agenda. Some institutions, such as Harvard University, have generated new lines with private money and made them available for researchers. Advanced Cell has also developed some of its own cells, including lines the company said it produced using a technique capable of leaving embryos intact.
During their “first 100 hours” Democrats in control of the U.S. House of Representatives passed a bill 253-274 that would ease funding rules for embryonic stem cell research. The U.S. Senate is expected to take up similar legislation next. President Bush, who used the first veto of his presidency last year to block a similar measure, has said he still opposes changes.
The U.S. stem cell community would benefit if politicians found a compromise that allowed federally funded researchers to work on some of the lines that have been developed in the past five years, said Jan-Eric Ahlfors, chief executive of Total ReCord Inc., a Worcester biotech company working on regenerative medicine therapies that do not use embryonic stem cells.
“The rest of the world has now surpassed the United States in both the quantity and the level of how far they have gotten in terms of this type of research, which is unusual because usually the U.S. is the leader in all medical research,” Mr. Ahlfors said.
As international scientists have moved ahead with embryonic stem cell research, some U.S. states have passed laws permitting the work. Some are also funding research.
In 2004, California voters approved the sale of bonds to finance $3 billion in adult and embryonic stem cell research. Litigation has delayed the California grants, but Connecticut has started handing out funding that is expected to total $10 million a year for 10 years.
The point of these efforts is to stake out a position in the field so that once federal funding restrictions are lifted, research will concentrate in the places that have already established experts and organizations, said Paul R. Pescatello, president of CURE, the Connecticut United for Research Excellence network for the state’s bioscience community. But states cannot fund all of the good research awaiting support, he said.
“When you look at the applications that came in for the state money, there is much more research to be funded than was funded,” Mr. Pescatello said. “State dollars are limited. California, too. Wherever you look. What’s striking about embryonic stem cell research is how many really good research proposals are out there.”
Legislation, funding and research initiatives, such as an agenda to create a center for regenerative medicine at the University of Massachusetts Medical School in Worcester, are also important to let businesses know that Massachusetts wants them, said Kevin O’Sullivan, president of Massachusetts Biomedical Initiatives, an economic development agency in Worcester.
“Perception is an important part of the business, and the competition is worldwide,” Mr. O’Sullivan said. “I’ve said it before. You can’t just legislate science.”
Mr. Caldwell of Advanced Cell said during a recent conference call that Advanced Cell is seeking corporate partners to bolster development of eye, skin and hemangioblast cells as treatments. In the past, the political risk of working with stem cells has hung over companies and investors, he said. Some legislative relief and some successes in the lab would help, he said.
“Once you start developing a platform technology and move out of the science and into what I call the translational process … you start a process that’s irreversible,” Mr. Caldwell said.
Contact business reporter Lisa Eckelbecker by e-mail at leckelbecker@telegram.com.
Yes, we were very, very, very lucky to get these tickets. My husband won the trip so we just have to pay for airfare. Woooohooo!!
You'll never believe it, Bridget...WE JUST GOT TICKETS TO THE SUPERBOWL!!!!!! Yeah, baby!!! GO BEARS!!!
Dspetry, under "tools", "my settings" - there's "bottom menu display" - change it to "everywhere". Then your tool bar will also be on the bottom of the page.
I didn't know it was like that on RB but that's exactly how I was envisioning it happening. It does seem like it would be easier the way you described but at least there's a way to do it.
Btw, welcome back!
Never realized I could do that. Thanks.
Matt, I think a great feature would be to be able to read someone's posts on a specific board. For example, I may want to read all of your posts on the Q&A board but not on all the other boards you post on. I have no idea how it could be done but would really like the ability to do so.
ACTC: WebAlert: Advanced Cell Technology Conference Call to Start Today at 12 Noon ET
ALAMEDA, Calif.-(Business Wire)-January 19, 2007 - Advanced Cell Technology, Inc. (OTCBB:ACTC), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, will host a live investor conference call with a simultaneous webcast, today at 12 noon Eastern, to update investors on recent news and events, as well as progress with respect to the Company's initiatives to develop stem cell-based therapies for a range of diseases and conditions.
During the conference call, William M. Caldwell, IV, Chairman and Chief Executive Officer of Advanced Cell Technology, will provide an overview of Company activities and news, will address investor questions and comment on the impact of the current political climate on the advancement of embryonic stem cell science and development. Mr. Caldwell will also discuss the Company's recently announced federal research grant from the National Institutes of Health. -0- *T WHO: Advanced Cell Technology WHAT: Investor Conference Call WHEN: Today, January 19, 2007, at 12 noon Eastern HOW: Callers within the United States may dial (800) 553-5275. When prompted, tell the operator that you would like to connect to the Advanced Cell conference call. International callers can dial (612) 332-1210. COST: The conference call is free of charge. WEBCAST: An online audio simulcast of the call will also be accessible at http://www.trilogy-capital.com/tcp/advanced_cell *T
No problem, Instruct - it's truly a great Ibox and I appreciate the time it's taken you to compile all the info.
Instruct, this is a great presentation by Addax that Spec found - you may want to consider adding to the Ibox.
http://www.addaxpetroleum.com/_media/Analysts_Day_Nov_Part3.pdf
This is great!
SmallCap Sentinel: Government Stem Cell Funding Sends Signal to Market
Thursday January 18, 6:30 am ET
IRVINE, Calif., Jan. 18, 2007 (PRIME NEWSWIRE) -- ``For an extended period of time, stem cell equities have busily conducted research under the black cloud of funding limitations,'' stated SmallCap Sentinel analyst D.R. Clark. ``Now, with the political landscape having changed so dramatically, stem cell equities are finding a more welcoming and perhaps brighter path.''
``Case in point, Advanced Cell Technology, Inc. (OTC BB:ACTC.OB - News) was awarded a research grant from the National Institutes of Health (NIH) in the amount of $204,439 in conjunction with a research project currently underway with one of its academic partners,'' Clark noted. ``I believe this exemplifies a dramatic change in the government's sentiment toward stem cell research while simultaneously enhancing confidence for Advanced Cell's business plan.''
``These types of funding events don't happen for every company that applies,'' Clark added. ``This is a defining moment for Advanced Cell Technology.''
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
http://biz.yahoo.com/pz/070118/112064.html
Advanced Cell Technology Announces Investor Conference Call to Be Held Friday January 19 to Discuss Key Events and Progress in Stem Cell-Based Therapeutic Programs
CEO William Caldwell to Review Impact of Federal and State Government Efforts to Spur Development of Human Embryonic Stem Cell Industry
ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB:ACTC), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, will host an investor conference call on Friday, January 19, at 12 noon Eastern, to discuss recent progress and events with respect to the Company’s initiatives to develop stem cell-based therapies for a range of diseases and conditions.
During the conference call, William M. Caldwell, IV, Chairman and Chief Executive Officer of Advanced Cell, will provide an overview of Company activities and news, and will address investor questions. Topics he will cover include the Company’s recently announced federal research grant from the National Institutes of Health.
Mr. Caldwell will also comment on the impact of the current political climate on the advancement of stem cell based science and technologies. Some states, including California and New Jersey, have enacted legislation to foster stem cell science. Additionally, the newly elected governor of New York State, Eliot Spitzer, recently advocated passage of a $2 billion 10-year bond initiative for research and development, at least half of which would be earmarked for stem cell research.
Interested investors within the United States can access the conference call by calling (800) 553-5275; when prompted tell the operator you would like to connect to the 'Advanced Cell Technology’ conference call. International callers can dial (612) 332-1210. An online audio web simulcast of the call will also be accessible at http://www.trilogy-capital.com/tcp/advanced_cell.
Welllll, after your last post here, I wonder why you might be deleted from the database? Hee, hee. :)
FWIW, Anadarko response to email asking about drilling in JDZ:
"The timing of drilling the well and announcing results remains uncertain. Sorry, but there is no further guidance I can provide."
Well, at litlle late but, I have to give credit where it's due - this link did come from Rick in an email. I just didn't know how to copy the entire email so just got the link. Should've posted that it was from him.
OT: Chevron Refinery Fire in California `Contained,' Police Say
By Joe Carroll
Jan. 15 (Bloomberg) -- A fire at Chevron Corp.'s Richmond, California, refinery was brought under control about two hours after it erupted, a police dispatcher said.
No one was injured in the blaze, which was reported at 5:22 a.m. local time at the plant, which accounts for 23 percent of San Ramon, California-based Chevron's U.S. refining capacity, said Vanessa Rodrigues, a dispatcher for the Richmond Police Department.
The refinery has a capacity of 225,000 barrels of crude oil a day, according to data compiled by Bloomberg.
To contact the reporter on this story: Joe Carroll in Chicago at jcarroll8@bloomberg.net
Mz, I know this is from awhile ago but just looking for something else on Sinopec's site and came up with a list of their International Subsidiaries. Nigeria Sinopec is not listed. The website may not have been updated lately but this could be the reason we were unable to find anything on Nigeria Sinopec.
http://english.sinopec.com/en-company/en-subsidiaries/index.shtml
Ok, can you translate that for me, I have no idea what that tells me? :)
If you haven't noticed, I'm most comfortable with miles - so I can convert if you can tell me what that means in km. Appreciate your help, Brez.
I hope so, too. :)
Ok, so that converts to about 1.2 miles. Sounds much closer than 6.21. Thanks for that, Brez.
Spec, it looks like you were right that the Belford Dolphin would make a stop before going to the GOM. However, according to this presentation by Anadarko, it will be drilling two wells in Ghana and Benin. See page 3. Scheduled for GOM in 3rd/4th quarter 2007.
http://www.anadarko.com/PDF/3Q06_operations_report.pdf
Ok, so really dumb question, I guess...10000m = about 6.21 miles - is that considered close in the oil world?